Maryland to Receive $90 Million From Purdue-Sackler Opioid Settlement, Bringing Total Recovery to $750 Million

Maryland will receive approximately $90 million from the historic $7.4 billion Purdue Pharma and Sackler family settlement that became legally effective May 1, 2026, according to an announcement from Attorney General Anthony Brown. The allocation brings the state's total opioid settlement recoveries to nearly $750 million—funds that will be distributed over the next eighteen years to address the devastating legacy of the prescription opioid epidemic.

The settlement marks the culmination of nearly a decade of litigation against Purdue Pharma, the manufacturer of OxyContin, and the Sackler family, whose aggressive marketing of prescription painkillers helped ignite the opioid crisis that has claimed over 800,000 American lives since 1999. Under the terms of the agreement, the Sackler family is permanently barred from selling opioids in the United States, and Purdue's manufacturing operations have been transferred to Knoa Pharma LLC under independent oversight.

"The opioid crisis has devastated Maryland families and communities, and the Sacklers must be held accountable for the role they played in fueling it," Brown said in a statement. "This settlement will support treatment, prevention, and recovery for Marylanders who have suffered for far too long."

Five Pillars of Recovery

The Maryland Office of Overdose Response, established to coordinate the state's opioid response strategy, has outlined five priority areas for settlement fund deployment. These recommendations reflect a comprehensive public health approach that moves beyond traditional law enforcement models to emphasize harm reduction, treatment access, and community-based recovery support.

Public safety initiatives under the plan include expanding alternatives to incarceration for drug-related offenses and strengthening crisis intervention programs that pair behavioral health clinicians with law enforcement. The state's co-response model, which dispatches mental health professionals alongside police to substance use emergencies, has shown promise in reducing arrests while connecting individuals to appropriate care.

Recovery support services represent another major funding priority, with plans to expand access to recovery centers that provide peer support, employment assistance, and housing navigation. These community-based hubs serve as entry points for individuals seeking help, offering low-barrier access to services without requiring immediate abstinence or formal treatment enrollment.

Treatment expansion focuses on increasing capacity for medication-assisted treatment—the evidence-based standard of care for opioid use disorder that combines FDA-approved medications like buprenorphine and methadone with counseling and behavioral therapies. Maryland has been a national leader in MAT expansion, particularly through its hub-and-spoke model that connects specialty treatment centers with primary care providers across the state.

Harm reduction services, including expanded naloxone distribution and street-based outreach programs, round out the strategic framework. Emily Keller, Maryland's special secretary of opioid response, emphasized the centrality of overdose reversal medication to the state's survival strategy. "We want to make sure that all Marylanders have access to naloxone, which is our number one tool for reversing an overdose," Keller said. "It's absolutely the number one life-saving tool, and I think something that Maryland has really thrived at."

Recent Investments Show the Model

The settlement announcement follows a recent $12.4 million award to 28 organizations across Maryland for overdose prevention and opioid education initiatives. These grants, funded through previous settlement allocations, demonstrate how Maryland is translating pharmaceutical accountability dollars into concrete community services.

Recipients span the full continuum of care, from pre-arrest diversion programs in Baltimore to mobile treatment units serving rural counties on the Eastern Shore. The geographic diversity reflects Maryland's unique challenges as a state that encompasses dense urban centers, sprawling suburbs, and isolated rural communities—each with distinct service gaps and population needs.

Baltimore City, which has borne a disproportionate share of Maryland's overdose burden, has secured hundreds of millions in separate settlement funds beyond the state allocation. The city's health department has pioneered innovative approaches including overdose prevention sites, though these remain politically contested and legally precarious under shifting federal policies.

The Settlement Structure

The $7.4 billion national settlement includes front-loaded payments designed to deliver the majority of funds during the first three years, when community need is most acute. The Sackler family contributed $1.5 billion in immediate payments, with additional installments of $500 million scheduled for May 2027 and May 2028, followed by $400 million in May 2029. Purdue Pharma contributed $900 million in the initial payment, with approximately $1.4 billion flowing annually through 2029.

Maryland's $90 million allocation will be disbursed over fifteen years, providing a sustained revenue stream for addiction services that contrasts with the boom-and-bust cycles of traditional grant funding. This predictability allows state and local agencies to make multi-year investments in workforce development, facility expansion, and program infrastructure.

The settlement also includes provisions for unprecedented transparency, requiring the public release of more than 30 million internal Purdue documents that detail the company's marketing strategies, physician targeting, and knowledge of addiction risks. These archives promise to fuel ongoing research, journalism, and litigation as communities seek to understand how the crisis was manufactured and who profited from the devastation.

Challenges Ahead

Despite the historic settlement, Maryland faces significant obstacles in converting dollars into outcomes. The state recorded over 2,000 overdose deaths in 2024, with fentanyl now present in the vast majority of fatalities. The synthetic opioid, often mixed unknowingly with other substances, has rendered obsolete many traditional harm reduction and treatment approaches designed for prescription opioid dependence.

Workforce shortages present another barrier. Maryland, like most states, lacks sufficient addiction medicine specialists, peer recovery coaches, and behavioral health clinicians to meet demand. Settlement-funded training programs and loan repayment initiatives aim to expand the workforce, but building clinical capacity takes years while the crisis demands immediate response.

Federal policy uncertainty compounds these challenges. Recent SAMHSA guidance restricting federal funds for fentanyl test strips and certain harm reduction services has created confusion about what activities can be supported with settlement dollars versus traditional grant funds. States must now navigate a complex patchwork of funding sources, each with distinct compliance requirements and ideological constraints.

A National Reckoning

Maryland's $90 million allocation represents a small fraction of the $50 billion-plus that states, counties, and cities will ultimately recover from opioid litigation. These settlements constitute the largest civil penalty in American history, dwarfing even the tobacco Master Settlement Agreement of 1998.

Whether this unprecedented financial reckoning translates into meaningful reduction in overdose deaths remains the central question facing public health officials. Early evidence from states like Kentucky and West Virginia suggests that sustained investment in naloxone distribution, medication-assisted treatment, and harm reduction can drive dramatic mortality reductions even amid the fentanyl era. But success requires not just funding but strategic deployment, rigorous evaluation, and political will to sustain evidence-based approaches against ideological opposition.

For Maryland families who have lost loved ones to overdose, the settlement offers neither justice nor closure. No financial penalty can restore the lives destroyed by corporate greed and regulatory failure. But the funds may yet save others—providing the medication, support, and dignity that could have prevented so many of the deaths that preceded them.

As Attorney General Brown noted, the settlement is ultimately about accountability. The Sacklers extracted an estimated $11 billion from Purdue Pharma while downplaying addiction risks and flooding communities with pills. That wealth will now flow back to the communities that suffered—slowly, imperfectly, but in quantities that could reshape the landscape of American addiction treatment if deployed with wisdom and sustained commitment.